Nothing Special   »   [go: up one dir, main page]

Hervent et al., 2012 - Google Patents

Molecular mechanisms of cardiotoxicity induced by ErbB receptor inhibitor cancer therapeutics

Hervent et al., 2012

View HTML
Document ID
9826480346145196365
Author
Hervent A
De Keulenaer G
Publication year
Publication venue
International journal of molecular sciences

External Links

Snippet

The introduction of the so-called “targeted therapies”, particularly those drugs that inhibit the activity of tyrosine kinases, has represented a remarkable progress in the treatment of cancer. Although these drugs improve survival rates in cancer, significant cardiotoxicity …
Continue reading at www.mdpi.com (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Similar Documents

Publication Publication Date Title
Hervent et al. Molecular mechanisms of cardiotoxicity induced by ErbB receptor inhibitor cancer therapeutics
Nami et al. Mechanisms underlying the action and synergism of trastuzumab and pertuzumab in targeting HER2-positive breast cancer
Maadi et al. Trastuzumab mechanism of action; 20 years of research to unravel a dilemma
Maennling et al. Molecular targeting therapy against EGFR family in breast cancer: progress and future potentials
Collins et al. Preclinical characteristics of the irreversible pan-HER kinase inhibitor neratinib compared with lapatinib: implications for the treatment of HER2-positive and HER2-mutated breast cancer
Lv et al. Molecular mechanisms and translational therapies for human epidermal receptor 2 positive breast cancer
Nahta et al. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer
Garrett et al. Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications
Ramakrishnan et al. Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin
Carrasco-García et al. Role of receptor tyrosine kinases and their ligands in glioblastoma
Agus et al. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer
Markovic et al. Current role of EGF receptor monoclonal antibodies and tyrosine kinase inhibitors in the management of head and neck squamous cell carcinoma
Okines et al. Trastuzumab: a novel standard option for patients with HER-2-positive advanced gastric or gastro-oesophageal junction cancer
Nami et al. The effects of pertuzumab and its combination with trastuzumab on HER2 homodimerization and phosphorylation
Mastro et al. Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients
Zhang et al. Recent progress and advances in HGF/MET-targeted therapeutic agents for cancer treatment
Arias-Pinilla et al. Therapeutic application of monoclonal antibodies in pancreatic cancer: advances, challenges and future opportunities
Mukai et al. Patritumab plus trastuzumab and paclitaxel in human epidermal growth factor receptor 2‐overexpressing metastatic breast cancer
Hafeez et al. New insights into ErbB3 function and therapeutic targeting in cancer
Overholser et al. Anti-tumor effects of peptide therapeutic and peptide vaccine antibody co-targeting HER-1 and HER-2 in esophageal cancer (EC) and HER-1 and IGF-1R in triple-negative breast cancer (TNBC)
Shu et al. A novel anti-HER2 antibody GB235 reverses Trastuzumab resistance in HER2-expressing tumor cells in vitro and in vivo
Gameiro et al. HER2-targeted immunotherapy and combined protocols showed promising antiproliferative effects in Feline mammary carcinoma cell-based models
Vathiotis et al. HER2 aberrations in non-small cell lung cancer: From pathophysiology to targeted therapy
Majumder HER3: toward the prognostic significance, therapeutic potential, current challenges, and future therapeutics in different types of cancer
Rubin et al. Molecular targeting of the human epidermal growth factor receptor-2 (HER2) genes across various cancers